2601: Reverse takeover of Amur Minerals: an exciting transformation into drug delivery

CEO Andrew Webb of Extruded Pharmaceuticals discusses Amur Minerals reverse takeover, which leads to an exciting transformation into drug delivery. Amur is currently classified as an AIM Rule 15 cash shell. It proposes to acquire 100 per cent. of EPL by way of an RTO under AIM Rule 14. Amur has called a general meeting of the Company in order to approve the proposed RTO, approve a change of name to CRISM Therapeutics, and approve a share consolidation of 1 new ordinary share for every 160 existing ordinary shares. EPL is a UK-based pharmaceutical company which was founded in March 2016. EPL has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed®, EPL's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This ensures that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. ChemoSeed addresses a significant, unmet medical need in the treatment of glioblastoma and high grade glioma. There are no current cures and present treatments merely seek to simply extend life, often by just a few months, with serious adverse side effects. Each ChemoSeed consist of a chemotherapeutic agent (irinotecan) and a bioresorbable polymer, both of which have been previously administered to the brain with no toxicity issues. This, combined with the target markets for ChemoSeed being unmet medical needs, means EPL could potentially receive conditional marketing authorisation in the UK on the back of positive Phase II clinical trial data. This authorisation could be received as early as 2028, therefore reducing the time and cost to commercialisation of irinotecan loaded ChemoSeeds for glioblastoma and high-grade glioma treatment. ------------ Some of the benefits of being a member of the SharePicker Investment Club:  *** The UK’s only MicroCap League: 100's of potential small cap investment ideas analysed and scored in relation to their growth, value, health, efficiency, momentum & potential.  *** Free Investment Book: How to become a MicroCap Millionaire (3 Step Strategy) by Justin Waite.  *** Weekly Live Webinar: Justin analyses potential investment ideas, fundamentally & technically. He discusses his own holdings together with portfolio management and other aspects of investing.  *** Blog: Justin will post a blog when he invests in a new company, on the day he invests.  *** My Watchlist: This is a list of companies Justin think's may have some decent investment potential.  *** Stock Requests: Members suggest stocks to be analysed on the webinar.  *** Company Analysis: Website based research function using the most important metrics that move share prices.  *** Targeted News: Access to news from small companies releasing significant news.  *** Resources: Learner videos on income statements, balance sheets, cash flow statements and charts plus spreadsheets to help you personally analyse companies.  *** Chat: Access to the Club's chat group.  For more information on the SharePickers Investment Club visit below: https://www.sharepickers.com Twitter @SharePickers https://twitter.com/SharePickers  LinkedIn https://www.linkedin.com/in/justinadamwaite/  NOTHING IN THIS PODCAST IS INVESTMENT ADVICE. PLEASE DO YOUR OWN RESEARCH OR IF YOU ARE UNSURE PLEASE SEEK PROFESSIONAL ADVICE FROM A REGULATED ADVISOR.